Vincerx PharmaVINC
VINC
About: Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.
Employees: 42
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
19% less funds holding
Funds holding: 26 [Q3] → 21 (-5) [Q4]
22.52% less ownership
Funds ownership: 35.68% [Q3] → 13.16% (-22.52%) [Q4]
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
84% less capital invested
Capital invested by funds: $7.89M [Q3] → $1.26M (-$6.63M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for VINC.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives
SAN MATEO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc. for a reverse merger transaction has been terminated.
Neutral
GlobeNewsWire
1 month ago
Vincerx Pharma, Inc. Announces Reverse Stock Split
Vincerx's Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025 Vincerx's Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025
Neutral
Business Wire
2 months ago
VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc. - VINC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Vincerx Pharma, Inc. (NasdaqCM: VINC) and Oqory, Inc. Pursuant to the terms of the agreement, at the closing of the transaction, Vincerx equity holders will hold about 5% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger.
Neutral
Business Wire
2 months ago
VINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Vincerx Pharma, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Vincerx Pharma, Inc. (NASDAQ: VINC) and Oqory, Inc. is fair to Vincerx shareholders. Upon completion of the proposed transaction, Vincerx equity holders will hold about 5% of the combined company. Halper Sadeh encourages Vincerx shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersade.
Neutral
Business Wire
2 months ago
Shareholder Alert: Ademi LLP Investigates Whether Vincerx Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Vincerx (Nasdaq: VINC) for possible breaches of fiduciary duty and other violations of law in its transaction with the Oqory. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the reverse merger transaction, Oqory merge with Vincerx and Oqory equity holders will own approximately 95% of the combined en.
Neutral
GlobeNewsWire
2 months ago
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.
Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company's pipeline Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company's pipeline
Neutral
GlobeNewsWire
3 months ago
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943
Also Exploring Strategic Alternatives to Complement Fundraising Efforts Also Exploring Strategic Alternatives to Complement Fundraising Efforts
Positive
Zacks Investment Research
5 months ago
What Makes Vincerx Pharma (VINC) a New Buy Stock
Vincerx Pharma (VINC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Benzinga
5 months ago
Penny Stock Cancer-Focused Vincerx Pharma Seeks Development Partner For 2 Early-Stage Blood Cancer Candidates
On Monday, Vincerx Pharma VINC shared updates on its ongoing Phase 1 studies of VIP943, VIP236, and enitociclib, which aim to address various blood cancers.
Neutral
GlobeNewsWire
5 months ago
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program's potential and validating the VersAptx™ Platform technology
Charts implemented using Lightweight Charts™